Defects in the interferon-gamma and interleukin-12 pathways.
Sergio D Rosenzweig, Steven M Holland
https://pubmed.ncbi.nlm.nih.gov/15661020/Actively Recruiting
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2026-10-29
150
Participants Needed
1
Research Sites
N/A
Total Duration
Tuberculosis TB is an infectious disease affecting many people worldwide. This study focuses on understanding the natural history of TB, including active and latent infections, and aims to gather information on the disease, its progression, and factors influencing susceptibility. Special attention is given to complications like drug resistance, co-infection with HIV, and immune system factors. The research also aims to provide training opportunities for infectious diseases trainees managing challenging TB cases. Participants with latent TB will have a single study visit involving a physical exam, medical history, and blood sample collection for testing. Those with active TB will have an initial visit with similar assessments, plus sputum samples if needed, and may optionally undergo a skin punch biopsy. Treatment for active TB will be provided as part of the study, and these participants may be asked to return for follow-up visits every 1 to 2 months during treatment. During the study, participants will undergo physical exams, medical history reviews, blood and sputum sample collections, and possibly skin biopsies. Researchers will analyze immune cell subsets, whole genome sequences of TB bacteria, and other biological specimens. The study tracks the number of TB patients followed, their disease status, and treatment responses. Participants will be monitored regularly while receiving treatment, with ongoing data collection to enhance understanding of TB disease and management.
CONDITIONS
Training Protocol on the Natural History of Tuberculosis
C
Carla D Williams, R.N.
S
Steven M Holland, M.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 1 visit
Participants with latent TB have one study visit including a physical exam, medical history, and blood sample collection.
1 visit (in-person)
Duration - Ongoing during treatment
Participants with active TB have an initial visit with physical exam, medical history, blood and sputum sample collection, and may have an optional skin biopsy. They receive treatment for active TB as part of the study.
Visits every 1 to 2 months during treatment
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Sergio D Rosenzweig, Steven M Holland
https://pubmed.ncbi.nlm.nih.gov/15661020/National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor